Cite
HARVARD Citation
Wang, J. et al. (2022). Combination of KIT and FLT3‐ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission. Hematological oncology. 40 (4), pp. 724-733. [Online].